In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition as amended and supplemented, and Article 10 of Decree No. 2-14-652 adopted for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties.<\/p>\n
This information was prepared by the notifying party, which is solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sectors concerned<\/strong><\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration project concerning the exclusive takeover by the company \u201cGallus Acqco Limited\u201d of the company \u201cGallus Topco Limited\u201d, the parent company of \u201cBiosynth Beteiligungs AG\u201d, and its subsidiaries, through the acquisition of the entire stake held by \u201cDr Urs Spitz\u201d amounting to 17.49%.<\/p>\n \u201cGallus Acqco Limited\u201d is an ad hoc company indirectly wholly owned by investment funds, vehicles and\/or accounts advised and managed by various subsidiaries of the company \u201cKKR & Co. Inc.\u201d (with its subsidiaries, \u201cKKR\u201d), registered under number 163222 and headquartered at 2nd<\/sup> Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey JE2 3QB.<\/p>\n \u201cKKR\u201d is an international investment company that offers alternative asset management solutions, as well as solutions for financial markets and insurance. KKR sponsors investment funds that invest in private equity, credit, and real estate assets, and has strategic partners managing hedge funds.<\/p>\n \u201cGallus Topco Limited\u201d is a Jersey company limited by shares, registered under number 139334 with the Jersey Financial Services Commission registry, headquartered at 2nd<\/sup> Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey, JE2 3QB. Gallus Topco Limited is a holding company.<\/p>\n \u201cBiosynth Beteiligungs AG\u201d is a Swiss public limited company, registered in the commercial register under number CH-320.3.075.694-1, headquartered at Rietlistrasse 4, 9422 Staad SG, Switzerland, is a group of companies active in the supply, development, and manufacture of a wide range of biochemical and chemical products, particularly research products and pharmaceutical and diagnostic products. The group offers a wide range of outsourced services throughout the value chain to its clients in the pharmaceutical and diagnostic sectors.<\/p>\n <\/p>\n Done in Rabat, March 19, 2026.<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition as amended and supplemented, and Article 10 of Decree No. 2-14-652 adopted for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties. This information was prepared by the notifying party, which is solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented. Names of the companies and groups concerned: The acquirer: \u201cGallus Acqco Limited\u201d; The target: \u201cGallus Topco Limited\u201d. Nature of the operation Exclusive takeover. Economic sectors concerned Laboratory product distribution in the life sciences sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e., March 30, 2026. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration project concerning the exclusive takeover by the company \u201cGallus Acqco Limited\u201d of the company \u201cGallus Topco Limited\u201d, the parent company of \u201cBiosynth Beteiligungs AG\u201d, and its subsidiaries, through the acquisition of the entire stake held by \u201cDr Urs Spitz\u201d amounting to 17.49%. \u201cGallus Acqco Limited\u201d is an ad hoc company indirectly wholly owned by investment funds, vehicles and\/or accounts advised and managed by various subsidiaries of the company \u201cKKR & Co. Inc.\u201d (with its subsidiaries, \u201cKKR\u201d), registered under number 163222 and headquartered at 2nd Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey JE2 3QB. \u201cKKR\u201d is an international investment company that offers alternative asset management solutions, as well as solutions for financial markets and insurance. KKR sponsors investment funds that invest in private equity, credit, and real estate assets, and has strategic partners managing hedge funds. \u201cGallus Topco Limited\u201d is a Jersey company limited by shares, registered under number 139334 with the Jersey Financial Services Commission registry, headquartered at 2nd Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey, JE2 3QB. Gallus Topco Limited is a holding company. \u201cBiosynth Beteiligungs AG\u201d is a Swiss public limited company, registered in the commercial register under number CH-320.3.075.694-1, headquartered at Rietlistrasse 4, 9422 Staad SG, Switzerland, is a group of companies active in the supply, development, and manufacture of a wide range of biochemical and chemical products, particularly research products and pharmaceutical and diagnostic products. The group offers a wide range of outsourced services throughout the value chain to its clients in the pharmaceutical and diagnostic sectors. Done in Rabat, March 19, 2026.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-47012","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n